Clinical Study Evaluating a Long-Acting Naltrexone Implant Under the FDA's 505(b)(2) Pathway ANAHEIM, CA - January 14, 2026 (NEWMEDIAWIRE) - BioCorRx Inc. (OTCID: BICX) (the "Company"), a developer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback